Obesity Clinical Trial
Official title:
Optimal Frequency of High-Intensity Interval Training for Centrally Obese Adults
The aim of this study is to examine the therapeutic effectiveness of two different exercise frequencies of high-intensity interval training (HIIT; once versus thrice weekly, with matched weekly exercise volume) on improving cardiometabolic risk factors in centrally obese adults.
Status | Recruiting |
Enrollment | 315 |
Est. completion date | December 31, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Aged above 18 years - Ethnic Chinese - Overweight (BMI =23 for Asian) - Centrally obese according to IDF and NCEP with Asian-specific cut-off (waist circumference =90 cm for males; =80 cm for females) - Males and females Exclusion Criteria: - Medical and somatic conditions that prevent brisk walking - Chronic diseases affecting mobility and motor function (e.g., neurological disease, musculoskeletal disorder, spinal cord injury, autoimmune, arthritis, Parkinson's Disease) - Chronic diseases affecting cardiorespiratory and metabolic health (e.g., cancers, cardio-/cerebrovascular diseases, heart disease, diabetes mellitus, pneumonia, chronic pulmonary diseases, nephritis, nephrosis) - Signs of cardiac arrhythmia indicated by aberrant electrocardiography during incremental VO2max test - Regular moderate-to-vigorous intensity exercise (=150 min weekly) in the past 3 months, as screened by a specially designed questionnaire - Daily smoking habit - Excess alcohol consumption (daily =30g for men, =20g for women) in the past six months - Claustrophobia - Surgery, therapy or medication for obesity or weight loss in the past six months (e.g., gastric bypass, gastric band, sleeve gastrectomy, gastric reduction duodenal switch, and dietitian-prescribed dietary program) |
Country | Name | City | State |
---|---|---|---|
Hong Kong | LKS Faculty of Medicine | Hong Kong |
Lead Sponsor | Collaborator |
---|---|
The University of Hong Kong |
Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Body Fat | Total body fat mass will be assessed using dual-energy X-ray absorptiometry (DXA) | Baseline and 4 months | |
Secondary | Change in Body Fat | Total body fat mass will be assessed using dual-energy X-ray absorptiometry (DXA) | Baseline and 8 months | |
Secondary | Change in Abdominal Visceral Fat | Abdominal visceral fat will be assessed using magnetic resonance imaging (MRI) | Baseline and 4 and 8 months | |
Secondary | Change in Abdominal Subcutaneous Fat | Abdominal subcutaneous fat will be assessed using magnetic resonance imaging (MRI) | Baseline and 4 and 8 months | |
Secondary | Change in Body Mass Index | Weight and height will be assessed using a calibrated electronic digital weighing scale and stadiometer respectively | Baseline and 4 and 8 months | |
Secondary | Change in Waist Circumference | Waist circumference will be assessed using an inelastic measuring tape to the nearest 0.1cm on bare skin | Baseline and 4 and 8 months | |
Secondary | Change in Systolic Blood Pressure | Resting systolic blood pressure will be assessed | Baseline and 4 and 8 months | |
Secondary | Change in Diastolic Blood Pressure | Resting diastolic blood pressure will be assessed | Baseline and 4 and 8 months | |
Secondary | Change in Fasting Glucose | Fasting glucose will be analyzed from venous blood by an accredited medical laboratory | Baseline and 4 and 8 months | |
Secondary | Change in Fasting Triglycerides | Fasting triglycerides will be analyzed from venous blood by an accredited medical laboratory | Baseline and 4 and 8 months | |
Secondary | Change in Fasting Low Density Lipoprotein Cholesterol (LDL-C) | Fasting LDL-C will be analyzed from venous blood by an accredited medical laboratory | Baseline and 4 and 8 months | |
Secondary | Change in Fasting High Density Lipoprotein Cholesterol (HDL-C) | Fasting HDL-C will be analyzed from venous blood by an accredited medical laboratory | Baseline and 4 and 8 months | |
Secondary | Change in Fasting Total Cholesterol | Fasting total cholesterol will be analyzed from venous blood by an accredited medical laboratory | Baseline and 4 and 8 months | |
Secondary | Change in Proportion of Metabolic Syndrome Diagnosis | Metabolic syndrome diagnosis will be evaluated with waist circumference, triglycerides, HDL-C, blood pressure, and fasting glucose | Baseline and 4 and 8 months | |
Secondary | Number of Adverse Events | Adverse events related or unrelated to training will be assessed | Baseline and 4 and 8 months | |
Secondary | Change in Organ Fat | Organ fat will be assessed using magnetic resonance imaging (MRI) | Baseline and 4 and 8 months | |
Secondary | Change in SF-12 Physical Component Summary Score | Physical health-related quality of life will be assessed using the Physical Component Summary Score of the 12-Item Short-Form Health Survey (SF-12) | Baseline and 4 and 8 months | |
Secondary | Change in SF-12 Mental Component Summary Score | Mental health-related quality of life will be assessed using the Mental Component Summary Score of the 12-Item Short-Form Health Survey (SF-12) | Baseline and 4 and 8 months | |
Secondary | Change in HADS-D Score | HADS-D score will be assessed using the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) | Baseline and 4 and 8 months | |
Secondary | Change in PHQ-9 Score | PHQ-9 score will be assessed using the Patient Health Questionnaire-9 (PHQ-9) | Baseline and 4 and 8 months | |
Secondary | Change in HADS-A Score | HADS-A score will be assessed using the Anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A) | Baseline and 4 and 8 months | |
Secondary | Change in GAD-7 Score | GAD-7 score will be assessed using the General Anxiety Disorder-7 (GAD-7) Questionnaire | Baseline and 4 and 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |